Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Validation of a Stability-Indicating Method for Methylseleno-L-Cysteine (L-SeMC).

Canady K, Cobb J, Deardorff P, Larson J, White JM, Boring D.

J Chromatogr Sci. 2016 Jan;54(1):22-7. doi: 10.1093/chromsci/bmv100. Epub 2015 Jul 21.

2.

Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.

Lubet RA, Scheiman JM, Bode A, White J, Minasian L, Juliana MM, Boring DL, Steele VE, Grubbs CJ.

Cancer Prev Res (Phila). 2015 Apr;8(4):296-302. doi: 10.1158/1940-6207.CAPR-14-0347. Epub 2015 Mar 11.

3.

Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.

Nicastro HL, Grubbs CJ, Margaret Juliana M, Bode AM, Kim MS, Lu Y, You M, Milne GL, Boring D, Steele VE, Lubet RA.

Cancer Prev Res (Phila). 2014 Feb;7(2):246-54. doi: 10.1158/1940-6207.CAPR-13-0164. Epub 2013 Dec 17.

4.

Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.

Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM; Cancer Prevention Network.

J Clin Pharmacol. 2013 Apr;53(4):403-12. doi: 10.1002/jcph.26. Epub 2013 Feb 22.

5.

Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.

Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velázquez-Martínez CA, Boring D, Kashfi K.

Biochem Pharmacol. 2012 Mar 15;83(6):715-22. doi: 10.1016/j.bcp.2011.12.018. Epub 2011 Dec 26.

PMID:
22222427
6.

Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.

Chattopadhyay M, Kodela R, Nath N, Barsegian A, Boring D, Kashfi K.

Biochem Pharmacol. 2012 Mar 15;83(6):723-32. doi: 10.1016/j.bcp.2011.12.019. Epub 2011 Dec 24.

PMID:
22209867
7.

Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo.

Chattopadhyay M, Kodela R, Nath N, Street CR, Velázquez-Martínez CA, Boring D, Kashfi K.

Biochem Pharmacol. 2012 Mar 15;83(6):733-40. doi: 10.1016/j.bcp.2011.12.020. Epub 2011 Dec 24.

PMID:
22209714
8.

Synthesis and biological activity of acetyl-protected hydroxybenzyl diethyl phosphates (EHBP) as potential chemotherapeutic agents.

Kodela R, Chattopadhyay M, Nath N, Cieciura LZ, Pospishill L, Boring D, Crowell JA, Kashfi K.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7146-50. doi: 10.1016/j.bmcl.2011.09.075. Epub 2011 Sep 22.

PMID:
22001089
9.

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.

Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ; Cancer Prevention Network.

Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. doi: 10.1158/1940-6207.CAPR-10-0313.

10.

Green tea extract-induced lethal toxicity in fasted but not in nonfasted dogs.

Wu KM, Yao J, Boring D.

Int J Toxicol. 2011 Feb;30(1):19-20. doi: 10.1177/1091581810387445. Epub 2010 Nov 22.

PMID:
21098339
11.

NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation.

Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K.

Cancer Lett. 2010 Dec 8;298(2):204-11. doi: 10.1016/j.canlet.2010.07.006. Epub 2010 Jul 31.

PMID:
20674154
12.

Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells.

Nath N, Chattopadhyay M, Kodela R, Tian S, Vlismas P, Boring D, Crowell JA, Kashfi K.

Biochem Pharmacol. 2010 Jun 15;79(12):1759-71. doi: 10.1016/j.bcp.2010.02.011. Epub 2010 Feb 24.

PMID:
20188076
13.

Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.

Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, Kopelovich L, Juliana MM, Grubbs CJ, Lubet RA.

Cancer Prev Res (Phila). 2009 Nov;2(11):951-6. doi: 10.1158/1940-6207.CAPR-09-0080.

14.

Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients.

Fatima N, Chelius D, Luke BT, Yi M, Zhang T, Stauffer S, Stephens R, Lynch P, Miller K, Guszczynski T, Boring D, Greenwald P, Ali IU.

Cancer Genomics Proteomics. 2009 Jan-Feb;6(1):41-9.

15.

Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.

Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ.

Cancer Prev Res (Phila). 2009 Feb;2(2):161-7. doi: 10.1158/1940-6207.CAPR-08-0134.

16.

Comparative bioavailability of sulindac in capsule and tablet formulations.

Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ; Cancer Prevention Network.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):674-9. doi: 10.1158/1055-9965.EPI-07-2510.

17.

Comparison of eyeblink conditioning in patients with superior and posterior inferior cerebellar lesions.

Gerwig M, Dimitrova A, Kolb FP, Maschke M, Brol B, Kunnel A, Böring D, Thilmann AF, Forsting M, Diener HC, Timmann D.

Brain. 2003 Jan;126(Pt 1):71-94.

PMID:
12477698
18.

Human-bacteria nitric oxide cycles in HIV-1 infection.

Zhang H, Boring D, Haverkos H.

Med Hypotheses. 2002 Jun;58(6):439-43.

PMID:
12323108
19.

Motor deficits cannot explain impaired cognitive associative learning in cerebellar patients.

Timmann D, Drepper J, Maschke M, Kolb FP, Böring D, Thilmann AF, Diener HC.

Neuropsychologia. 2002;40(7):788-800.

PMID:
11900729
20.
21.

Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups.

Berglund BA, Boring DL, Wilken GH, Makriyannis A, Howlett AC, Lin S.

Prostaglandins Leukot Essent Fatty Acids. 1998 Aug;59(2):111-8. Erratum in: Prostaglandins Leukot Essent Fatty Acids 1999 Feb;60(2):140.

PMID:
9774174
22.
23.

Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors.

Boring DL, Berglund BA, Howlett AC.

Prostaglandins Leukot Essent Fatty Acids. 1996 Sep;55(3):207-10.

PMID:
8931121
24.

Forskolin carbamates: binding and activation studies with type I adenylyl cyclase.

Robbins JD, Boring DL, Tang WJ, Shank R, Seamon KB.

J Med Chem. 1996 Jul 5;39(14):2745-52.

PMID:
8709105
25.

Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid.

Pinto JC, Potié F, Rice KC, Boring D, Johnson MR, Evans DM, Wilken GH, Cantrell CH, Howlett AC.

Mol Pharmacol. 1994 Sep;46(3):516-22.

PMID:
7935333
26.

Trifunctional agents as a design strategy for tailoring ligand properties: irreversible inhibitors of A1 adenosine receptors.

Boring DL, Ji XD, Zimmet J, Taylor KE, Stiles GL, Jacobson KA.

Bioconjug Chem. 1991 Mar-Apr;2(2):77-88.

Supplemental Content

Loading ...
Support Center